Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA

Shoichi Aoki, Norihide Shimizu, Jun Ichi Koyama, Yoshiko Kato, Masaru Kitagawa, Kazuo Okumura, Yusuke Tanigawara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We have studied the influence of Gly-Ala-Arg peptide at the N-terminus and the oligosaccharide at Asn184 on the clearance of tissue plasminogen activator (t-PA). In order to intensify the influence of these structural features, Gln117 t-PA, which is a mutant tissue plasminogen activator (mt-PA) expressed in mouse C127 cells, was used for the investigation. It is altered to remove a high mannose type oligosaccharide by the mutation of an amino acid from Asn117 to Gln. We isolated 4 variants of Gln117 t-PA by cation- exchange chromatography, which are abbreviated as S-I, S-II, L-I and L-II. These variants originated from the heterogeneity of the peptide chains (S- chain, 527 amino acids, L-chain, 530 amino acids) and oligosaccharide (Type I, 2 oligosaccharides, Type II, 1 oligosaccharide). Pharmacokinetics of these variants were investigated after single intravenous administration to male rats at a dose of 250 μg/kg. Significant differences in pharmacokinetic parameters were observed among these variants, but there was no considerable difference in fibrin clot lysis time (FCLT) activity. Gly-Ala-Arg peptide at the N-terminus increased the CL(t), whereas the oligosaccharide at Asn184 decreased the CL(t). Moreover, the effects of the N-terminal peptide and the oligosaccharide on the CL(t) were independent of each other. Our study with Gln117 t-PA revealed the role of the N-terminal peptide found in the L-chain produced during the processing of t-PA precursor.

Original languageEnglish
Pages (from-to)477-481
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume23
Issue number4
Publication statusPublished - 2000 Apr

Fingerprint

Tissue Plasminogen Activator
Oligosaccharides
Peptides
Amino Acids
Pharmacokinetics
Fibrin Clot Lysis Time
Mannose
Intravenous Administration
Cations
Chromatography
Mutation

Keywords

  • Gln117 t-PA
  • L-chain
  • S-chain
  • Tissue plasminogen activator
  • Variant

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Aoki, S., Shimizu, N., Koyama, J. I., Kato, Y., Kitagawa, M., Okumura, K., & Tanigawara, Y. (2000). Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA. Biological and Pharmaceutical Bulletin, 23(4), 477-481.

Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA. / Aoki, Shoichi; Shimizu, Norihide; Koyama, Jun Ichi; Kato, Yoshiko; Kitagawa, Masaru; Okumura, Kazuo; Tanigawara, Yusuke.

In: Biological and Pharmaceutical Bulletin, Vol. 23, No. 4, 04.2000, p. 477-481.

Research output: Contribution to journalArticle

Aoki, S, Shimizu, N, Koyama, JI, Kato, Y, Kitagawa, M, Okumura, K & Tanigawara, Y 2000, 'Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA', Biological and Pharmaceutical Bulletin, vol. 23, no. 4, pp. 477-481.
Aoki S, Shimizu N, Koyama JI, Kato Y, Kitagawa M, Okumura K et al. Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA. Biological and Pharmaceutical Bulletin. 2000 Apr;23(4):477-481.
Aoki, Shoichi ; Shimizu, Norihide ; Koyama, Jun Ichi ; Kato, Yoshiko ; Kitagawa, Masaru ; Okumura, Kazuo ; Tanigawara, Yusuke. / Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA. In: Biological and Pharmaceutical Bulletin. 2000 ; Vol. 23, No. 4. pp. 477-481.
@article{5f324455080e4487bd99d94e7a3311bf,
title = "Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA",
abstract = "We have studied the influence of Gly-Ala-Arg peptide at the N-terminus and the oligosaccharide at Asn184 on the clearance of tissue plasminogen activator (t-PA). In order to intensify the influence of these structural features, Gln117 t-PA, which is a mutant tissue plasminogen activator (mt-PA) expressed in mouse C127 cells, was used for the investigation. It is altered to remove a high mannose type oligosaccharide by the mutation of an amino acid from Asn117 to Gln. We isolated 4 variants of Gln117 t-PA by cation- exchange chromatography, which are abbreviated as S-I, S-II, L-I and L-II. These variants originated from the heterogeneity of the peptide chains (S- chain, 527 amino acids, L-chain, 530 amino acids) and oligosaccharide (Type I, 2 oligosaccharides, Type II, 1 oligosaccharide). Pharmacokinetics of these variants were investigated after single intravenous administration to male rats at a dose of 250 μg/kg. Significant differences in pharmacokinetic parameters were observed among these variants, but there was no considerable difference in fibrin clot lysis time (FCLT) activity. Gly-Ala-Arg peptide at the N-terminus increased the CL(t), whereas the oligosaccharide at Asn184 decreased the CL(t). Moreover, the effects of the N-terminal peptide and the oligosaccharide on the CL(t) were independent of each other. Our study with Gln117 t-PA revealed the role of the N-terminal peptide found in the L-chain produced during the processing of t-PA precursor.",
keywords = "Gln117 t-PA, L-chain, S-chain, Tissue plasminogen activator, Variant",
author = "Shoichi Aoki and Norihide Shimizu and Koyama, {Jun Ichi} and Yoshiko Kato and Masaru Kitagawa and Kazuo Okumura and Yusuke Tanigawara",
year = "2000",
month = "4",
language = "English",
volume = "23",
pages = "477--481",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Influence of N-terminal peptide and oligosaccharide on the clearance of t-PA

AU - Aoki, Shoichi

AU - Shimizu, Norihide

AU - Koyama, Jun Ichi

AU - Kato, Yoshiko

AU - Kitagawa, Masaru

AU - Okumura, Kazuo

AU - Tanigawara, Yusuke

PY - 2000/4

Y1 - 2000/4

N2 - We have studied the influence of Gly-Ala-Arg peptide at the N-terminus and the oligosaccharide at Asn184 on the clearance of tissue plasminogen activator (t-PA). In order to intensify the influence of these structural features, Gln117 t-PA, which is a mutant tissue plasminogen activator (mt-PA) expressed in mouse C127 cells, was used for the investigation. It is altered to remove a high mannose type oligosaccharide by the mutation of an amino acid from Asn117 to Gln. We isolated 4 variants of Gln117 t-PA by cation- exchange chromatography, which are abbreviated as S-I, S-II, L-I and L-II. These variants originated from the heterogeneity of the peptide chains (S- chain, 527 amino acids, L-chain, 530 amino acids) and oligosaccharide (Type I, 2 oligosaccharides, Type II, 1 oligosaccharide). Pharmacokinetics of these variants were investigated after single intravenous administration to male rats at a dose of 250 μg/kg. Significant differences in pharmacokinetic parameters were observed among these variants, but there was no considerable difference in fibrin clot lysis time (FCLT) activity. Gly-Ala-Arg peptide at the N-terminus increased the CL(t), whereas the oligosaccharide at Asn184 decreased the CL(t). Moreover, the effects of the N-terminal peptide and the oligosaccharide on the CL(t) were independent of each other. Our study with Gln117 t-PA revealed the role of the N-terminal peptide found in the L-chain produced during the processing of t-PA precursor.

AB - We have studied the influence of Gly-Ala-Arg peptide at the N-terminus and the oligosaccharide at Asn184 on the clearance of tissue plasminogen activator (t-PA). In order to intensify the influence of these structural features, Gln117 t-PA, which is a mutant tissue plasminogen activator (mt-PA) expressed in mouse C127 cells, was used for the investigation. It is altered to remove a high mannose type oligosaccharide by the mutation of an amino acid from Asn117 to Gln. We isolated 4 variants of Gln117 t-PA by cation- exchange chromatography, which are abbreviated as S-I, S-II, L-I and L-II. These variants originated from the heterogeneity of the peptide chains (S- chain, 527 amino acids, L-chain, 530 amino acids) and oligosaccharide (Type I, 2 oligosaccharides, Type II, 1 oligosaccharide). Pharmacokinetics of these variants were investigated after single intravenous administration to male rats at a dose of 250 μg/kg. Significant differences in pharmacokinetic parameters were observed among these variants, but there was no considerable difference in fibrin clot lysis time (FCLT) activity. Gly-Ala-Arg peptide at the N-terminus increased the CL(t), whereas the oligosaccharide at Asn184 decreased the CL(t). Moreover, the effects of the N-terminal peptide and the oligosaccharide on the CL(t) were independent of each other. Our study with Gln117 t-PA revealed the role of the N-terminal peptide found in the L-chain produced during the processing of t-PA precursor.

KW - Gln117 t-PA

KW - L-chain

KW - S-chain

KW - Tissue plasminogen activator

KW - Variant

UR - http://www.scopus.com/inward/record.url?scp=0034014690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034014690&partnerID=8YFLogxK

M3 - Article

C2 - 10784431

AN - SCOPUS:0034014690

VL - 23

SP - 477

EP - 481

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 4

ER -